Selective CDK4/6 inhibitors (CDK4/6i) act by blocking the cyclin D1/CDK4/6 complex and inhibit cell cycle transition and thus, cancer cell proliferation as well as endocrine resistance in breast carcinoma [2]. Here, CDK4 is linked to cancer.